Osteonecrosis of the jaw associated with ziv-aflibercept. [PDF]
J Gastrointest Oncol, 2016 Medication-related osteonecrosis of the jaw (MRONJ) has been associated with medications that include bisphosphonates (BPs), denosumab, bevacizumab and sunitinib. Ziv-aflibercept is a recombinant human vascular endothelial growth factor (VEGF) receptor which has been used to treat patients with various advanced solid tumors.
Mawardi H +6 more
europepmc +4 more sources
Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes [PDF]
Journal of Ophthalmic & Vision Research, 2023 Purpose: To evaluate the effects of intravitreal ziv-aflibercept injections (IVZ) on subfoveal choroidal thickness (SCT) as well as on central macular thickness (CMT) and on best corrected visual acuity (BCVA) changes in eyes with center-involved ...
Siamak Moradian +5 more
doaj +2 more sources
A combination of suprachoroidal injection of triamcinolone using a custom-made needle and intravitreal Ziv-aflibercept every eight weeks to manage naïve/denovo central DME: a single-center retrospective case series [PDF]
International Journal of Retina and VitreousBackground Previous studies have shown promising effects of combining intravitreal bevacizumab and suprachoroidal injection of triamcinolone acetonide in treating DME. However, further research is needed.
Ameen Marashi +4 more
doaj +2 more sources
Retinal Toxicity of Intravitreal Injection of Ziv-Aflibercept in Albino Rabbits. [PDF]
Transl Vis Sci Technol, 2018 To evaluate retinal toxicity of ziv-aflibercept, a drug that had been approved for use for patients with colon cancer.Twenty-two albino rabbits were injected intravitreally with 0.1 mL of ziv-aflibercept solution into the experimental eye and 0.1-mL saline into the control eye. Twelve were used for electroretinogram (ERG) at 4-weeks follow-up.
Ramon D +5 more
europepmc +3 more sources
Toxicology Reports, 2023 Sulfur mustard (SM)-induced ocular injury is characterized by an acute inflammatory response that may become chronic or enter a latent phase with delayed pathology.
Ariel Gore +6 more
doaj +2 more sources
Ziv-aflibercept in metastatic colorectal cancer. [PDF]
Biologics, 2014 The combination of cytotoxic chemotherapy and antiangiogenic agents has become a conventional treatment option for patients with metastatic colorectal cancer. Ziv-aflibercept is a fusion protein which acts as a decoy receptor for vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF); it was approved in combination with
Patel A, Sun W.
europepmc +6 more sources
Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study [PDF]
International Journal of Retina and VitreousPurpose To evaluate the structural and functional changes in eyes with neovascular age related macular degeneration (nAMD) in a real-world setting, using Treat and Extend protocol (T&E), comparing four antiangiogenic agents.
Tereza Kanadani +4 more
doaj +2 more sources
Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 year [PDF]
Taiwan Journal of Ophthalmology, 2020 PURPOSE: The purpose of this study was to compare intravitreal ziv-aflibercept (IVZ) monotherapy to intravitreal bevacizumab (IVB) monotherapy in patients with exudative age-related macular degeneration (eAMD).
Sumit Randhir Singh +7 more
doaj +2 more sources
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer [PDF]
BMC Cancer, 2019 Background Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II dose ...
John H. Strickler +19 more
doaj +2 more sources
Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy [PDF]
Indian Journal of Ophthalmology, 2019 Purpose: To report the visual and anatomical outcomes of intravitreal ziv-aflibercept (IVZ) and bevacizumab (BVZ) monotherapy in treatment-naive polypoidal choroidal vasculopathy (PCV).
Sumit Randhir Singh +3 more
doaj +2 more sources